Propranolol’s Impact on Metabolic and Lipidomic Signatures in Severe Burn Injury

Study Background and Research Question

Severe burn injuries, particularly those affecting more than 20% of total body surface area, provoke an intense, sustained hypermetabolic state. This response is largely driven by elevated catecholamine release from sympathetic nervous system activation, leading to increased energy expenditure, widespread catabolism, adipose tissue remodeling, and systemic inflammation. While beta-blockers like propranolol are established in clinical practice for attenuating this hypermetabolic state, the precise metabolic mechanisms underlying their benefit have remained incompletely understood. The referenced phase II randomized controlled trial (Ann Surg 2023;278:519–529) sought to fill this knowledge gap by applying comprehensive metabolomic and lipidomic analyses to elucidate how propranolol modulates metabolic pathways in burn patients.

Key Innovation from the Reference Study

The primary innovation of this investigation is the integration of untargeted metabolomics and lipidomics with clinical outcomes in a randomized controlled setting. By directly analyzing adipose tissue from severely burned patients treated with propranolol versus controls, the study deciphers how beta-blockade affects core metabolic circuits—particularly those governing energy metabolism, nucleotide turnover, and fatty acid composition. Notably, the research pinpoints propranolol’s ability to normalize aberrant metabolomic signatures, shifting lipid profiles from proinflammatory to antiinflammatory states and attenuating stress signaling within adipose tissue. This systems-level approach clarifies the biochemical basis for propranolol’s clinical efficacy in burn care.

Methods and Experimental Design Insights

The trial enrolled 52 patients with acute burns covering ≥20% total body surface area, randomly assigned to either propranolol (n=23) or standard care (n=29). Propranolol dosing was titrated to reduce heart rate below 100 beats per minute, in keeping with established protocols. Key outcome measures included clinical markers (heart rate, resting energy expenditure), inflammatory status, lipidomic profiles, untargeted metabolomic analyses of adipose tissue, and molecular pathway interrogation.

Adipose tissue samples were subjected to high-resolution mass spectrometry to perform untargeted metabolomics and lipidomics. Pathway-level analyses evaluated shifts in energy metabolism (e.g., glycolytic and tricarboxylic acid cycle intermediates), nucleotide metabolism, catecholamine degradation, and fatty acid species. Targeted immunoblotting assessed the activation state of hormone-sensitive lipase (HSL) at serine 660 and markers of endoplasmic reticulum (ER) stress, such as phospho-JNK.

Core Findings and Why They Matter

• Metabolic pathway normalization: Propranolol significantly modulated several core metabolic pathways within adipose tissue, particularly those involved in energy production and nucleotide metabolism (reference study).
• Lipidomic remodeling: Treated patients exhibited lower levels of proinflammatory saturated fatty acids, including palmitic acid, alongside a higher ratio of polyunsaturated fatty acids. This shift fosters an antiinflammatory adipose phenotype.
• Attenuation of lipolytic and stress signaling: Propranolol reduced the activation of HSL at serine 660—a key regulator of lipolysis—and decreased ER stress signaling as indicated by reduced phospho-JNK.
• Clinical relevance: These molecular adaptations corresponded with improved physiological stress responses, supporting the role of adipose tissue as a mediator of hypermetabolism and systemic inflammation after burns.

Collectively, the findings reveal that propranolol’s clinical benefits are underpinned by targeted normalization of metabolic and inflammatory derangements in adipose tissue, rather than by non-specific suppression of global metabolism.

Comparison with Existing Internal Articles

The trial’s focus on metabolic pathway modulation in adipose tissue after burn injury intersects with ongoing research into cellular energy metabolism and mitochondrial dysfunction. For example, recent work on NADH/NAD⁺ ratio as a biomarker in Leigh syndrome models demonstrates the critical role of reduced nicotinamide adenine dinucleotide in mitochondrial electron transport chain research and disease modeling. The use of advanced LC-MS/MS quantification parallels the present study's untargeted metabolomics approach, reinforcing the value of precision metabolic profiling in translational research.

Furthermore, internal reviews have discussed how NADH serves as a central coenzyme in glycolysis, the TCA cycle, and mitochondrial redox regulation. These insights underscore the importance of monitoring metabolic fluxes and redox state, not only in inherited mitochondrial disorders but also in acquired metabolic stress, as seen in burns. Propranolol’s modulation of energy metabolism and fatty acid turnover echoes the broader theme of targeting metabolic nodes to influence systemic outcomes—an approach increasingly relevant in photocatalytic cancer therapy and diabetic nephropathy research as well.

Limitations and Transferability

While the randomized controlled design and integration of multi-omics profiling strengthen the study’s conclusions, several limitations merit consideration. The cohort size, though among the largest for such mechanistic burn studies, remains modest. The focus on adipose tissue, while justified by its role in hypermetabolism, means that parallel effects in muscle or liver were not directly assessed. Additionally, metabolomic signatures were measured at discrete time points, potentially missing dynamic fluctuations during recovery.

Transferability to other patient populations—such as those with chronic metabolic diseases or pediatric cohorts—requires caution, particularly given differences in baseline adipose tissue function and beta-adrenergic signaling. Nonetheless, the study’s demonstration that targeted metabolic modulation can reverse maladaptive stress responses offers a framework for future interventions across inflammatory and hypermetabolic states.

Protocol Parameters

• Propranolol dosing: Titrate to achieve heart rate <100 bpm; adjust dose based on patient tolerance and hemodynamic response as in the reference trial.
• Sample collection: Obtain adipose tissue biopsies at standardized post-injury intervals for omics analysis.
• Metabolomic profiling: Employ untargeted LC-MS/MS for comprehensive pathway analysis; validate key findings with targeted immunoblotting for markers like HSL (Ser660) and phospho-JNK.
• Lipidomic analysis: Quantify saturated and polyunsaturated fatty acid species to track antiinflammatory remodeling.
• Workflow suggestion: For studies in mitochondrial dysfunction, apply parallel quantification of NADH/NAD⁺ ratios using validated LC-MS/MS methods.

Research Support Resources

To facilitate metabolic and mitochondrial pathway research—whether in burn injury, mitochondrial disease models, or advanced metabolic profiling—researchers may use NADH (Reduced-form Nicotinamide Adenine Dinucleotide) CAS No. 58-68-4 (SKU C8749) from APExBIO. This reagent enables precise assessment of NADH/NAD⁺ ratios and supports workflows in mitochondrial electron transport chain research, cellular energy metabolism studies, and translational models, as highlighted in recent internal articles. Use of research-grade NADH helps ensure reproducibility and accuracy in mechanistic investigations of metabolic adaptation and stress responses.